VNDA · Healthcare · $300M
$4.99-0.78%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“Fanapt 매출이 3,600만 달러로 전 분기 대비 22%, 전년 동기 대비 23% 늘었어요 — 조현병에서 양극성장애로 처방 범위가 넓어진 효”
In the company's words · 2026 2분기 earnings call